In 2004, Sandoz acquired Sabex, headquartered in Boucherville, Canada. This strategic acquisition allowed Sandoz to establish a new presence for Sandoz in Canada, the sixth largest generics market worldwide, to gain an attractive global growth platform in the fast-growing injectable generics business and to get an FDA-approved manufacturing facility.
Sandoz Canada develops, manufactures and distributes injectable and ophthalmic generic pharmaceutical products for the hospital and retail markets. It has nearly 700 employees countrywide, most of whom are located at the Boucherville facilities. Injectable and ophthalmic products are a special category of generics involving unique processes that require specific expertise. This distinction has enabled Sandoz Canada to become the internationally renowned Sandoz Centre of Excellence for injectable products. We currently have 209 molecules produced under various dosage forms: injectables, ampoules and vials; ophthalmic solutions, suspensions and ointments; suppositories; oral and topical forms.
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Our success depends on the creativity and performance of our associates.
Exforge® receives US regulatory approval as a new and highly effective treatment option for patients with high blood pressure...